Deerfield Management ANIP Position
Exited3-Fund ConvergenceDeerfield Management exited their position in ANI PHARMACEUTICALS INC (ANIP) in Q3 2024, after holding the stock for 4 quarters.
The position was first reported in Q4 2023 and has been tracked across 4 quarterly 13F filings.
ANIP is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 20.0% of float with 9.7 days to cover, indicating significant bearish positioning against the stock.
About ANI PHARMACEUTICALS INC
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Full company profile →Short Interest
20.0%
9.7 days to cover
Deerfield Management ANIP Position History
Frequently Asked Questions
Does Deerfield Management own ANIP?
No. Deerfield Management exited their position in ANI PHARMACEUTICALS INC (ANIP) in Q3 2024. They previously held the stock for 4 quarters.
How many hedge funds own ANIP?
3 specialist biotech hedge funds currently hold ANIP, including Deep Track Capital, Tang Capital Management, Driehaus Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy ANIP?
Deerfield Management's position in ANIP was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's ANIP position increasing or decreasing?
Deerfield Management completely exited their ANIP position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ANIPCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →